Marona-Lewicka Danuta, Kurrasch-Orbaugh Deborah M, Selken Jennifer R, Cumbay Medhane G, Lisnicchia Joshua G, Nichols David E
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907, USA.
Psychopharmacology (Berl). 2002 Oct;164(1):93-107. doi: 10.1007/s00213-002-1141-z. Epub 2002 Jul 19.
There is substantial evidence that lisuride can produce effects linked to 5-HT(1A) receptor occupancy. Nevertheless, this action has generally been ignored in the mechanism of action of lisuride, in favor of an exclusive role for dopamine receptors in considering its antiparkinsonian effects, or an exclusive role of 5-HT(2A/2C) receptor activation in hallucinogenesis. These conclusions are surprising when one considers that the potent interaction of lisuride with 5-HT(1A) receptors has been demonstrated in several different laboratories and that activation of 5-HT(1A) and 5-HT(1B) receptors can modulate dopaminergically mediated responses.
The lack of full substitution of lisuride for lysergic acid diethylamide (LSD) in drug discrimination experiments and induction of a pronounced 5-HT syndrome by this compound at relatively low doses convinced us to execute two series of experiments that might explain the primary mechanism responsible for lisuride-mediated biological effects and its paradoxical classification as a dopamine agonist in the literature.
In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine. Lisuride produced a significant dose-related increase in flat body posture, forepaw treading, and lower-lip retraction which reflect a modulation of behavior by action at central 5-HT(1A) receptors. Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD. Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective 5-HT(1A) agonist LY 293284. The hypothermic effect of lisuride was prevented by pre-injection of pMPPI, but not by ketanserin or haloperidol.
We have demonstrated that the behavioral effects of low doses of lisuride are clearly mediated by stimulation of 5-HT(1A) receptors.
有大量证据表明,利苏瑞肽可产生与5-HT(1A)受体占据相关的效应。然而,在利苏瑞肽的作用机制中,这一作用通常被忽视,在考虑其抗帕金森病作用时更倾向于多巴胺受体的唯一作用,或者在致幻作用中更倾向于5-HT(2A/2C)受体激活的唯一作用。当人们考虑到利苏瑞肽与5-HT(1A)受体的强效相互作用已在多个不同实验室得到证实,并且5-HT(1A)和5-HT(1B)受体的激活可调节多巴胺能介导的反应时,这些结论令人惊讶。
在药物辨别实验中,利苏瑞肽不能完全替代麦角酸二乙酰胺(LSD),且该化合物在相对低剂量时可诱导明显的5-HT综合征,这使我们进行了两个系列的实验,以解释利苏瑞肽介导生物学效应的主要机制及其在文献中被矛盾地归类为多巴胺激动剂的原因。
在药物辨别研究中,利苏瑞肽完全模拟了5-HT(1A)激动剂LY 293284的作用,仅部分替代LSD和DOI,且不能替代(+)-苯丙胺。利苏瑞肽使平身姿势、前爪踩踏和下唇回缩显著增加,且呈剂量相关性,这反映了其通过作用于中枢5-HT(1A)受体对行为的调节。只有选择性5-HT(1A)拮抗剂pMPPI[4-碘-N-[2-[4-(甲氧基苯基)-1-哌嗪基]乙基]-N-2-吡啶基-苯甲酰胺盐酸盐]能够有效抑制利苏瑞肽产生的所有5-HT综合征行为,而pMPPI对LSD诱导的任何行为均无影响。利苏瑞肽使大鼠体温呈剂量依赖性降低,其效力与选择性5-HT(1A)激动剂LY 293284相似。预先注射pMPPI可预防利苏瑞肽的降温作用,但酮色林或氟哌啶醇则不能。
我们已经证明,低剂量利苏瑞肽的行为效应明显是由5-HT(1A)受体的刺激介导的。